-+ 0.00%
-+ 0.00%
-+ 0.00%

Pasithea Therapeutics Announces Tablet PK Data From Ongoing Phase 1/1b Open-Label Study Evaluating PAS-004 In Adult Patients With Neurofibromatosis Type 1

Benzinga·11/21/2025 17:40:42
Listen to the news

-- Tablet PK exposure increases proportionally with an increase in dose --

-- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with improved predictability and reduced variability --

-- Tablet steady state showing Cmax/Cmin ratio <2 --

MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), today announced positive tablet PK data from ongoing Phase 1/1b open-label study evaluating PAS-004 in adult patients with neurofibromatosis type 1 (NF1) with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas (NCT06961565).